아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - human insulin (recombinant dna origin) - suspension for injection - 100 iu/ml - insulins and analogues for injection, intermediate- or long-acting combined with fast-acting - humulin m3 - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis

아르메니아 - 영어 - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

lilly france s.a.s. - insulin human (recombinant dna) - suspension for injection - 100iu/ml

아르메니아 - 영어 - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

lilly france s.a.s. - insulin human (recombinant dna) - suspension for injection - 100iu/ml

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

eli lilly and company ltd - insulin isophane human - suspension for injection - 100unit/1ml

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

eli lilly and company ltd - insulin isophane human; insulin soluble human - suspension for injection - 70unit/1ml ; 30unit/1ml

몰타 - 영어 - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - insulin human, rdna - suspension for injection - insulin human (rdna) 100 iu/ml - drugs used in diabetes

몰타 - 영어 - Medicines Authority

eli lilly nederland b.v papendorpseweg 83, 3528 bj, utrecht, nl-3991, netherlands - insulin human, rdna - solution for injection - insulin human (rdna) 100 iu - drugs used in diabetes

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - human insulin (recombinant dna origin) - suspension for injection - 100 iu/ml - insulin (human) - humulin - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin, quantity: 100 iu/ml - injection, suspension - excipient ingredients: sodium hydroxide; glycerol; metacresol; zinc oxide; phenol; dibasic sodium phosphate heptahydrate; protamine sulfate; hydrochloric acid; water for injections - this product accepted for registration as 'currently supplied' at the time of commencement of the act. humulin is indicated for the treatment of insulin-dependent diabetic patients.

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - insulin, human, recombinant dna origin 100 [iu] (as 70% isophane insulin and 30% regular insulin) - suspension for injection - 100 iu/ml - active: insulin, human, recombinant dna origin 100 [iu] (as 70% isophane insulin and 30% regular insulin) excipient: dibasic sodium phosphate heptahydrate glycerol hydrochloric acid as 10% solution for ph adjustment metacresol phenol protamine sulfate sodium hydroxide as 10% solution for ph adjustment water for injection zinc oxide - humulin is indicated for the treatment of insulin-requiring diabetes mellitus